Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
2.075
-0.075 (-3.49%)
Aug 28, 2026, 12:05 PM EDT - Market open
Acrivon Therapeutics Employees
As of December 31, 2025, Acrivon Therapeutics had 76 total employees, including 74 full-time and 2 part-time employees. The number of employees decreased by 2 or -2.56% compared to the previous year.
Employees
76
Change (1Y)
-2
Growth (1Y)
-2.56%
Revenue / Employee
n/a
Profits / Employee
-$976,645
Market Cap
88.92M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 76 | -2 | -2.56% | 74 | 2 |
| Dec 31, 2024 | 78 | 17 | 27.87% | 75 | 3 |
| Dec 31, 2023 | 61 | 17 | 38.64% | 58 | 3 |
| Sep 30, 2023 | 59 | 17 | 40.48% | 56 | 3 |
| Jun 30, 2023 | 53 | 17 | 47.22% | 50 | 3 |
| Mar 31, 2023 | 48 | 12 | 33.33% | 45 | 3 |
| Dec 31, 2022 | 44 | - | - | 41 | 3 |
| Sep 30, 2022 | 42 | - | - | 39 | 3 |
| Jun 30, 2022 | 36 | - | - | 35 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Adicet Bio | 102 |
| Fortress Biotech | 78 |
| Verrica Pharmaceuticals | 76 |
| ImmuCell | 73 |
| MAIA Biotechnology | 13 |
| Atara Biotherapeutics | 10 |
| Dogwood Therapeutics | 8 |
ACRV News
- 11 days ago - Acrivon Therapeutics reports Q2 EPS (43c), consensus (50c) - TheFly
- 15 days ago - Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts - GlobeNewsWire
- 16 days ago - Acrivon Therapeutics Quarterly report: Q2 2026 - Filings
- 16 days ago - Acrivon Therapeutics Earnings release: Q2 2026 - Filings
- 16 days ago - Acrivon Therapeutics Slides: Corporate presentation - Filings
- 23 days ago - Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study - GlobeNewsWire
- 5 weeks ago - Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics assumed with an Outperform at Oppenheimer - TheFly